This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was:  Recruiting
Eli Lilly and Company
Information provided by:
Hospital Authority, Hong Kong Identifier:
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis

Condition Intervention Phase
Lung Neoplasms Drug: gemcitabine, carboplatin Procedure: surgery Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery

Resource links provided by NLM:

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • pathological response rate [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • progression-free survival [ Time Frame: 18 months ]
  • overall survival [ Time Frame: 18 months ]
  • quality of life measurements [ Time Frame: 18 months ]

Estimated Enrollment: 50
Study Start Date: May 2005
Estimated Study Completion Date: February 2007

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Histologically or cytologically proven, newly diagnosed primary bronchogenic non-small cell lung cancer
  • Measurable or evaluable tumour on chest X-ray or CT scan.
  • No multiple ipsilateral or contralateral parenchymal tumours
  • Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00563160

Contact: Patricia Poon, Dr (852) 2958 2310

Queen Elizabeth Hospital Recruiting
Hong Kong, China
Sub-Investigator: Che Mun Poon, Dr         
Sub-Investigator: Chun Key Law, Dr         
Sub-Investigator: Roger Ngan, Dr         
Sub-Investigator: Chung Kong Kwan, Dr         
Sub-Investigator: Cheuk Kin Lo, Dr         
Sub-Investigator: Johnny Chan, Dr         
Sub-Investigator: TK Au Yong, Dr         
Sub-Investigator: Ting Lok Kwan, Dr         
Sub-Investigator: Stella Cheung, Dr         
Sub-Investigator: Timothy Yip         
Sponsors and Collaborators
Hospital Authority, Hong Kong
Eli Lilly and Company
Principal Investigator: Siu Kie Au, Dr Department of Clinical Oncology, Queen Elizabeth Hospital
  More Information

Additional Information: Identifier: NCT00563160     History of Changes
Other Study ID Numbers: (193-h)in QE/EC/I
Study First Received: November 21, 2007
Last Updated: July 6, 2010

Keywords provided by Hospital Authority, Hong Kong:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 22, 2017